Jared Kaltwasser

Investigators said several new anemia therapies are in development, and many of them may help wide swaths of patients.

Patients who had ruxolitinib added to their prophylactic regimens had lower rates of acute and chronic graft-versus-host disease (GVHD).

People with muscle-specific kinase myasthenia gravis appear to have more active antibody responses in general, the study found.

A new report found only about 2.8% of people with myelodysplastic syndromes (MDS) have JAK2 mutations.

The new recommendations from the World Health Organization (WHO) urge viewing the totality of evidence when evaluating biosimilar products.

The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis.

A feasibility study shows many providers intended to continue using the tool, although some said they did not have sufficient time or did not need the tool.

The new report found polygenic risk scores likely will not help identify patients at highest risk.

The risk of death among people with primary myelofibrosis (PMF) dropped by 53% after ruxolitinib’s introduction, the study found, although the data also suggested only 8.5% of patients were prescribed the drug.

Just 26 cases have been reported in which myasthenia gravis (MG) symptoms appeared following vaccination.

While repetitive nerve stimulation (RNS) remains a mainstay of myasthenia gravis diagnosis, investigators said it does not appear to yield prognostic insights.

Features of polycythemia vera (PV) can easily be misattributed to other causes, such as iron depletion or arterial hypertension.

Overall survival, cancer-specific survival and progression-free survival were all negatively affected by elevated C-reactive protein levels, this study found.

The article suggests the inflammatory components of myasthenia gravis have been underexplored in the effort to develop new therapies.

Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC).

The study also found, however, that transplant outcomes appear to be worse for Black African American patients who have primary myelofibrosis (PMF), although the study utilized a small sample size.

Patients with myelofibrosis (MF) who achieved a spleen response while taking ruxolitinib and lost it had survival outcomes similar to patients who did not respond, according to results from a real-world study.

A different type of test may improve diagnosis for some patients with myasthenia gravis (MG).

The authors identified 2 subgroups with non–small cell lung cancer (NSCLC) who had different responses to common cancer therapies.

The results of the futility analysis also suggest the therapy leads to significant clinical benefits.

The authors say newer treatment options for small cell lung cancer (SCLC) may lead to improvement in this area of high unmet need.

Evidence suggests as many as 29% of people with myeloproliferative neoplasms (MPN) or myelodysplastic syndrome (MDS)/MPN have chronic kidney disease.

The study found 143 loci where somatic copy numbers were varied based on genetic ancestry.

Overall survival and recurrence-free survival showed substantial improvement when physicians more closely followed quality recommendations for non–small cell lung cancer (NSCLC).

The patient, an 83-year-old man, experienced onset of myasthenia gravis after a severe SARS-CoV-2 infection.

The report helps clarify the urban/rural divide in cancer outcomes and the digital divide in telehealth access.

The method had high rates of sensitivity and specificity, although its sensitivity was somewhat lower in cases of localized prostate cancer.

Artificial intelligence (AI) improved detection of actionable lung nodules without leading to higher rates of false positives, the study found.

Even patients with the mildest symptoms of myasthenia gravis said they experienced negative quality-of-life (QOL) effects from the disease.

Such cases of eosinophilic esophagitis (EoE) are rare, but they can be treated with the typical therapies for EoE.